196 related articles for article (PubMed ID: 32487090)
1. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M
BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090
[TBL] [Abstract][Full Text] [Related]
2. A study of the immune infiltrate and patient outcomes in esophageal cancer.
Conroy MJ; Kennedy SA; Doyle SL; Hayes B; Kavanagh M; van der Stok EP; O'Sullivan K; Cathcart MC; Reynolds JV; Lysaght J
Carcinogenesis; 2021 Apr; 42(3):395-404. PubMed ID: 32940666
[TBL] [Abstract][Full Text] [Related]
3. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H
J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428
[TBL] [Abstract][Full Text] [Related]
5. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
6. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma.
Schiffmann LM; Göbel H; Löser H; Schorn F; Werthenbach JP; Fuchs HF; Plum PS; Bludau M; Zander T; Schröder W; Bruns CJ; Kashkar H; Quaas A; Gebauer F
BMC Cancer; 2019 May; 19(1):531. PubMed ID: 31151416
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
8. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
Noble F; Mellows T; McCormick Matthews LH; Bateman AC; Harris S; Underwood TJ; Byrne JP; Bailey IS; Sharland DM; Kelly JJ; Primrose JN; Sahota SS; Bateman AR; Thomas GJ; Ottensmeier CH
Cancer Immunol Immunother; 2016 Jun; 65(6):651-62. PubMed ID: 27020682
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition.
Donlon NE; Davern M; Sheppard AD; O'Connell F; Dunne MR; Hayes C; Mylod E; Ramjit S; Temperley H; Mac Lean M; Cotter G; Bhardwaj A; Butler C; Conroy MJ; O'Sullivan J; Ravi N; Donohoe CL; Reynolds JV; Lysaght J
Front Immunol; 2022; 13():823225. PubMed ID: 35154142
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer.
Hynes CF; Kwon DH; Vadlamudi C; Lofthus A; Iwamoto A; Chahine JJ; Desale S; Margolis M; Kallakury BV; Watson TJ; Haddad NG; Marshall MB
Ann Thorac Surg; 2018 Oct; 106(4):1002-1007. PubMed ID: 29859152
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma.
Loeser H; Kraemer M; Gebauer F; Bruns C; Schröder W; Zander T; Alakus H; Hoelscher A; Buettner R; Lohneis P; Quaas A
J Immunol Res; 2020; 2020():2862647. PubMed ID: 33029538
[TBL] [Abstract][Full Text] [Related]
13. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.
Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM
J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
16. Exploring the immune microenvironment in small bowel adenocarcinoma using digital image analysis.
Sidi FA; Bingham V; McQuaid S; Craig SG; Turkington RC; James JA; Humphries MP; Salto-Tellez M
PLoS One; 2023; 18(8):e0289355. PubMed ID: 37527282
[TBL] [Abstract][Full Text] [Related]
17. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus.
Schoemmel M; Loeser H; Kraemer M; Wagener-Ryczek S; Hillmer A; Bruns C; Thelen M; Schröder W; Zander T; Lechner A; Buettner R; Schlösser H; Gebauer F; Quaas A;
Clin Transl Oncol; 2021 Aug; 23(8):1601-1610. PubMed ID: 33566304
[TBL] [Abstract][Full Text] [Related]
18. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
[TBL] [Abstract][Full Text] [Related]
19. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA
Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299
[TBL] [Abstract][Full Text] [Related]
20. High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma.
Rauser S; Langer R; Tschernitz S; Gais P; Jütting U; Feith M; Höfler H; Walch A
BMC Cancer; 2010 Nov; 10():608. PubMed ID: 21054833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]